Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

作者：John H. Krystal, John M. Kane, Christoph U. Correll, David P. Walling, Matthew Leoni, Sridhar Duvvuri, Shrinal Patel, Ih Chang, Philip Iredale, Lillian Frohlich, Stacey Versavel, Pamela Perry, Raymond Sanchez, John J. Renger · 发表于：The Lancet · 年份：2022 · DOI：10.1016/s0140-6736(22)01990-0 · 被引用次数：113 · 研究领域：Receptor Mechanisms and Signaling、Nicotinic Acetylcholine Receptors Study、Vagus Nerve Stimulation Research